Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics

• Grifols will apply artificial intelligence technologies, including large language models, to speed up the development of new biopharma therapeutics
• Agreement is latest Grifols initiative to reinforce the robustness of its therapeutic pipeline and strengthen its innovation culture
  
  

BARCELONA, Spain, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people’s health and well-being for more than 110 years, today has announced a collaboration agreement with Google Cloud to harness its powerful technologies such as artificial intelligence (AI) to greatly accelerate the development of new Grifols biopharma medicines.

AI featuring large language models will be applied across the drug-development life cycle, including identifying potential therapeutic candidates and managing clinical trial programs, to significantly reduce the time required to bring novel treatments to market.

Fundamental to this will be a new Grifols scientific information platform with deep Grifols-owned internal and external data sets that can be rapidly mined for insights on diseases and pharmacology. Discovering disease-identifying biomarkers at an early stage can lead to more effective treatments for patients. It can also surface trends among specific cohorts, yielding more personalized medicine and individual care regimens while greatly enhancing health outcomes.

Grifols will explore new applications and use cases for data and AI in the biopharma sector. It will also work with Google Cloud on sharing best practices in innovation including new technologies, prototype quick testing and rapid scaling. Reenergized Grifols internal processes will enhance team agility, lift productivity and reinforce a culture of innovation.

“Grifols will reinvent biopharma medicine as we know it so we can bring more treatments to more patients in more parts of the world,” said Albert Grifols Coma-Cros, Grifols Chief Scientific Innovation Officer. “Turbocharging our extensive knowledge of biopharma and plasma science with the most advanced data technologies from Google Cloud will benefit patients and society.”

“We are thrilled to partner with Grifols to help the company accelerate its R&D efforts and improve patient care," said Isaac Hernández, GM of Google Cloud Iberia. "Our data and generative AI capabilities can help Grifols glean new insights, accelerate the discovery of new drugs and therapies, and improve the efficiency of its manufacturing processes."

For media inquiries:

Grifols Press Office



Tel. 2

Investors:

Investors Relations Department & Sustainability

-  Tel. 1

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with more than 390 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2022, Grifols’ economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.